Field Medical Unveils Revolutionary 6-Month Data for VT Treatment at Upcoming Symposium

Field Medical's Groundbreaking Advances in Ventricular Tachycardia Treatment

Field Medical, Inc., known for its cutting-edge work in pulsed field ablation (PFA) technology, is poised to make significant waves at the upcoming 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium) in Philadelphia.

Taking place on October 10-11, 2025, this prestigious symposium will feature three key presentations from Field Medical, showcasing the first-in-human data collected over six months for its innovative FieldForce™ Ablation System. This system is well-regarded for its capability to target ventricular tachycardia (VT), a condition marked by abnormal heart rhythms that can lead to serious health complications.

The symposium will highlight substantial findings from the clinical trial, which involved the pioneering use of high-voltage focal PFA as a treatment for scar-related VT. Dr. Vivek Reddy is slated to present the groundbreaking presentation titled "High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia Final 6-Month Outcomes of the First-in-Human VCAS Trial". This presentation will occur on Friday, October 10, from 3:50–4:00 PM. In addition to Dr. Reddy's presentation, Dr. Cory Tschabrunn will explore insights from a porcine model of chronic infarction, emphasizing the preclinical research that backs their findings.

The excitement continues with a pre-recorded live case demonstration by Dr. Reddy on October 11, showcasing the practical application of these technologies with his demonstration titled "Image Guided High Voltage VT Ablation" between 12:35–1:55 PM.

Field Medical's chairman, Mark Wisniewski, expressed pride in the contributions being made through this symposium, emphasizing the urgency and necessity for technological innovations in the treatment of VT. "Our six-month outcomes showcase PFA's potential in addressing these challenging arrhythmias, reflecting the unique strengths of our method and technology," Wisniewski remarked.

In conjunction with this groundbreaking data being showcased, Field Medical also announced significant leadership changes aimed at fortifying the company's dedication to innovation and strategic development. Dr. Steven Mickelsen, the company's founder, has transitioned into the role of Chief Technology Officer. In this position, he will drive further clinical advancements and design innovations for the FieldForce Ablation System. Meanwhile, Kit Schneider has been appointed Chief Strategy Officer, taking the helm of long-term strategy objectives, corporate partnerships, and company growth. Schneider commented, "Field Medical has achieved incredible progress regarding PFA's role in treating ventricular tachycardia. My priorities include preparing the company for its next growth phase while reinforcing partnerships to ensure our innovations reach physicians and patients globally."

Founded in 2022, Field Medical is dedicated to advancing PFA technologies designed specifically for complex cardiac arrhythmias. The FieldForce™ Ablation System cleverly integrates a focal catheter design with the proprietary FieldBending™ energy, which aims to facilitate precise and efficient ablation processes. This initiative is anticipated to markedly improve outcomes for managing both ventricular and atrial arrhythmias. Additionally, in 2024, Field Medical earned the distinction of Breakthrough Device Designation, marking its entry into the FDA's TAP Pilot Program for its pivotal work focused on ventricular tachycardia.

The FieldForce™ Ablation System remains under investigational status, as stipulated by federal law. For more information, please visit Field Medical's official website. Follow them on LinkedIn, X, and YouTube for updates on their pioneering works.

Conclusion

The upcoming VT Symposium offers an exciting opportunity for medical professionals to engage with the latest advancements in health technology catering to ventricular tachycardia. Field Medical's presentations are particularly anticipated due to their innovative approaches and potential for significant clinical impact in the realm of cardiac arrhythmias.